Development of novel vaccine to reduce galectin-3 for Alzheimer's disease

Abstract

Alzheimer's disease (AD) is the major cause of dementia and one of the intractable neurodegenerative diseases. There are many reports that neuroinflammation is related to the pathomechanism of AD and microglia have an important role in neuroinflammation of central nervous system. Galectin-3 is a member of the lectin family and has the function related to proinflammatory processes. Recently, some reports said that serum or cerebrospinal fluid galectin-3 levels were elevated in AD patients. In this study, we developed a novel vaccine to reduce galectin-3 and examined the effect of vaccination using inflammation model of mice.